CARMAT announces its participation in key investor and scientific conferences during the 2nd half of 2022
Paris, August 30, 2022 – 6 p.m. CEST
CARMAT (FR0010907956, ALCAR, PEA-PME eligible), designer and developer of the most advanced total artificial heart in the world, aimed at offering a therapeutic alternative to patients suffering from end-stage biventricular heart failure, today announces the participation of various members of its management team at the following investor and scientific conferences during the 2nd half of 2022.
To receive all of CARMAT’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.